Chatani M, Teshima T, Inoue T, Yoshino K, Ikegami N, Hirai K, Shimakage M
Department of Radiation Therapy, Center for Adult Diseases, Osaka, Japan.
Laryngoscope. 1991 Jun;101(6 Pt 1):626-9. doi: 10.1288/00005537-199106000-00009.
Specific antibody responses against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) were evaluated. Thirty-five sera from pretreatment patients of nasopharyngeal carcinoma (NPC) and 12 from healthy adults were tested. Although the anti-EBNA2 response did not show any correlation with T stage, overall stage, or histopathology, it showed a correlation with the N stage of the disease. In a serological follow-up study, 17 (85%) of 20 patients showed a correlation on the change of antibody levels to EBNA2 and clinical progression. This suggests that EBNA2 serology might represent a useful marker relative to tumor status.
评估了针对爱泼斯坦-巴尔病毒编码核抗原2（EBNA2）的特异性抗体反应。检测了35份鼻咽癌（NPC）预处理患者的血清以及12份健康成年人的血清。尽管抗EBNA2反应与T分期、总体分期或组织病理学均无相关性，但与疾病的N分期相关。在一项血清学随访研究中，20例患者中有17例（85%）显示抗体水平对EBNA2的变化与临床进展相关。这表明EBNA2血清学可能是与肿瘤状态相关的有用标志物。
